ELITE PHARMACEUTICALS, INC. (OTCMKTS:ELTP) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On June 14, 2018, Elite Pharmaceuticals, Inc. ("Elite" or the “Company") filed its annual report on Form 10-K for the year ended March 31, 2018 and, thereafter, issued a press release announcing its financial results for that quarter. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
As noted in the press release, the Company will host a conference call at 1:00 PM Eastern Standard Time (EST) on Friday, June 15, 2018, to provide a general business update. Elite will respond to various stockholder questions submitted prior to the call.
Conference Call Information
| Date: | Friday, June 15, 2018 |
| Time: | 1:00 PM EDT |
| Dial-in numbers: | 1-800-346-7359 (domestic) |
| 1-973-528-0008 (international) | |
| Conference number: | |
| Questions: | dianne@elitepharma.com by 8:00 PM EDT on Thursday, June 14, 2018 |
| Audio Replay: | http://elite.irpass.com/events_presentations |
| Item 7.01 | Regulation FD Disclosure. |
The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, "Results of Operations and Financial Condition," Item 7.01, "Regulation FD Disclosure" and Item 9.01 "Financial Statements and Exhibits" of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
| Item 9.01 | Financial Statements and Exhibits. |
| 99.1 | Press Release dated June 14, 2018 |
ELITE PHARMACEUTICALS INC /NV/ ExhibitEX-99.1 2 tv496518_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Elite Pharmaceuticals,…To view the full exhibit click here
About ELITE PHARMACEUTICALS, INC. (OTCMKTS:ELTP)
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is principally engaged in the development and manufacture of oral, controlled-release products. The Company develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA’s) for generic products and New Drug Applications (NDA’s) for branded products. The Company owns approximately six different approved ANDA’s. The Company’s product, SequestOx, is an immediate-release Oxycodone Hydrochloride containing sequestered Naltrexone, which incorporates five milligram, 10 milligram, 15 milligram, 20 milligram and 30 milligram doses of oxycodone into capsules. SequestOx is used for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.